Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
J Virol Methods ; 326: 114910, 2024 May.
Article in English | MEDLINE | ID: mdl-38452823

ABSTRACT

INTRODUCTION: SARS-CoV-2 is usually diagnosed from naso-/oropharyngeal swabs which are uncomfortable and prone to false results. This study investigated a novel diagnostic approach to Covid-19 measuring volatile organic compounds (VOC) from patients' urine. METHODS: Between June 2020 and February 2021, 84 patients with positive RT-PCR for SARS-CoV-2 were recruited as well as 54 symptomatic individuals with negative RT-PCR. Midstream urine samples were obtained for VOC analysis using ion mobility spectrometry (IMS) which detects individual molecular components of a gas sample based on their size, configuration, and charge after ionization. RESULTS: Peak analysis of the 84 Covid and 54 control samples showed good group separation. In total, 37 individual specific peaks were identified, 5 of which (P134, 198, 135, 75, 136) accounted for significant differences between groups, resulting in sensitivities of 89-94% and specificities of 82-94%. A decision tree was generated from the relevant peaks, leading to a combined sensitivity and specificity of 98% each. DISCUSSION: VOC-based diagnosis can establish a reliable separation between urine samples of Covid-19 patients and negative controls. Molecular peaks which apparently are disease-specific were identified. IMS is an additional non-invasive and cheap device for the diagnosis of this ongoing endemic infection. Further studies are needed to validate sensitivity and specificity.


Subject(s)
COVID-19 , Volatile Organic Compounds , Humans , COVID-19/diagnosis , SARS-CoV-2 , Volatile Organic Compounds/analysis , Ion Mobility Spectrometry , Sensitivity and Specificity , COVID-19 Testing
2.
Pulmonology ; 30(1): 43-52, 2024.
Article in English | MEDLINE | ID: mdl-36797151

ABSTRACT

PURPOSE: A1Antitrypsin deficiency (AATD) pathogenic mutations are expanding beyond the PI*Z and PI*S to a multitude of rare variants. AIM: to investigate genotype and clinical profile of Greeks with AATD. METHODS: Symptomatic adult-patients with early-emphysema defined by fixed airway obstruction and computerized-tomography scan and lower than normal serum AAT levels were enrolled from reference centers all over Greece. Samples were analyzed in the AAT Laboratory, University of Marburg-Germany. RESULTS: Included are 45 adults, 38 homozygous or compound heterozygous for pathogenic variants and 7 heterozygous. Homozygous were 57.9% male, 65.8% ever-smokers, median (IQR) age 49.0(42.5-58.5) years, AAT-levels 0.20(0.08-0.26) g/L, FEV1(%predicted) 41.5(28.8-64.5). PI*Z, PI*Q0, and rare deficient allele's frequency was 51.3%, 32.9%,15.8%, respectively. PI*ZZ genotype was 36.8%, PI*Q0Q0 21.1%, PI*MdeficientMdeficient 7.9%, PI*ZQ0 18.4%, PI*Q0Mdeficient 5.3% and PI*Zrare-deficient 10.5%. Genotyping by Luminex detected: p.(Pro393Leu) associated with MHeerlen (M1Ala/M1Val); p.(Leu65Pro) with MProcida; p.(Lys241Ter) with Q0Bellingham; p.(Leu377Phefs*24) with Q0Mattawa (M1Val) and Q0Ourem (M3); p.(Phe76del) with MMalton (M2), MPalermo (M1Val), MNichinan (V) and Q0LaPalma (S); p.(Asp280Val) with PLowell (M1Val); PDuarte (M4), YBarcelona (p.Pro39His). Gene-sequencing (46.7%) detected Q0GraniteFalls, Q0Saint-Etienne, Q0Amersfoort(M1Ala), MWürzburg, NHartfordcity and one novel-variant (c.1A>G) named Q0Attikon.Heterozygous included PI*MQ0Amersfoort(M1Ala), PI*MMProcida, PI*Mp.(Asp280Val), PI*MOFeyzin. AAT-levels were significantly different between genotypes (p = 0.002). CONCLUSION: Genotyping AATD in Greece, a multiplicity of rare variants and a diversity of rare combinations, including unique ones were observed in two thirds of patients, expanding knowledge regarding European geographical trend in rare variants. Gene sequencing was necessary for genetic diagnosis. In the future the detection of rare genotypes may add to personalize preventive and therapeutic measures.


Subject(s)
alpha 1-Antitrypsin Deficiency , Adult , Humans , Male , Middle Aged , Female , alpha 1-Antitrypsin Deficiency/diagnosis , alpha 1-Antitrypsin Deficiency/epidemiology , alpha 1-Antitrypsin Deficiency/genetics , alpha 1-Antitrypsin/genetics , Greece/epidemiology , Genotype
4.
Pneumologie ; 75(3): 191-200, 2021 Mar.
Article in German | MEDLINE | ID: mdl-33728628

ABSTRACT

The present addendum of the guideline for the diagnosis and treatment of asthma (2017) complements new insights into the diagnosis and management of asthma as well as for the newly approved drugs for the treatment of asthma. Current, evidence-based recommendations on diagnostic and therapeutic approaches are presented for children and adolescents as well as for adults with asthma.


Subject(s)
Asthma , Pulmonary Medicine , Adolescent , Adult , Asthma/diagnosis , Asthma/drug therapy , Asthma/epidemiology , Austria , Child , Humans , Societies, Medical
5.
Pneumologie ; 75(5): 344-352, 2021 May.
Article in English | MEDLINE | ID: mdl-33307557

ABSTRACT

BACKGROUND: Accumulating evidence on the role of blood eosinophils as a biomarker prompted the Global Initiative for Chronic Obstructive Lung Disease (GOLD) committee to refine the existing treatment algorithm by incorporating eosinophil counts into treatment recommendations. However, there is a lack of data on when, why and how frequently such blood tests and other measures are being performed by German private respiratory specialists. METHODS: A questionnaire evaluating doctors' opinions on the use of diagnostic measures at initial diagnosis and during follow-up, including blood eosinophil count in patients with COPD, was completed by 27 respiratory specialists. Medical records from the past 12 months of 251 patients treated by the same physicians were reviewed retrospectively to investigate the use of these measures. RESULTS: Body plethysmography (100 % of doctors) and chest X-ray (96.3 %) were the most commonly used measures according to the doctor's questionnaire; other measures were COPD assessment test (CAT; 85.2 %) and blood eosinophil count (81.5 %). The evaluation of patients' medical records revealed that body plethysmography was performed in 72.7 %, the CAT in 61.8 % and chest X-ray in 40.6 % of patients. Blood eosinophil count was measured in 7.2 %. CONCLUSIONS: In line with the GOLD recommendations, these results confirm that lung function, imaging and patient-reported outcome questionnaires play a crucial role in managing COPD. Our analyses reveal that measurement of the blood eosinophil count gained importance due to physicians' increased awareness of these cells as a useful biomarker. However, this test seems to be performed mainly for initial diagnosis and not on a regular basis.


Subject(s)
Eosinophils , Pulmonary Disease, Chronic Obstructive , Germany , Humans , Leukocyte Count , Pulmonary Disease, Chronic Obstructive/diagnosis , Retrospective Studies
7.
Pneumologie ; 71(12): 849-919, 2017 12.
Article in German | MEDLINE | ID: mdl-29216678

ABSTRACT

The present guideline is a new version and an update of the guideline for the diagnosis and treatment of asthma, which replaces the previous version for german speaking countries from the year 2006. The wealth of new data on the pathophysiology and the phenotypes of asthma, and the expanded spectrum of diagnostic and therapeutic options necessitated a new version and an update. This guideline presents the current, evidence-based recommendations for the diagnosis and treatment of asthma, for children and adolescents as well as for adults with asthma.


Subject(s)
Asthma/diagnosis , Asthma/therapy , Asthma/classification , Asthma/etiology , Austria , Germany , Humans , Prognosis , Risk Factors , Societies, Medical
8.
Pneumologie ; 71(9): 580-586, 2017 Sep.
Article in German | MEDLINE | ID: mdl-28449136

ABSTRACT

Background and objectives Alpha-2 Macroglobulin (A2M) is a plasma protein with proteolytic effects on many proteases. In patients with an inborn alpha-1 antitrypsin deficiency (AATD) the homeostasis between proteases and antiproteases is disturbed. The aim of this study was to compare the levels of AAT and A2 M in patients and controls. We hypothesized that in patients with AATD A2 M levels are elevated. Methods Patients with AATD (polymorphism Pi*ZZ, Pi*SZ, Pi*MZ and rare gene variants) as well as healthy volunteers (Pi*MM) were tested for A2 M and AAT levels. The concentration of the proteins was measured by nephelometry. The polymorphisms Pi*Z and Pi*S were detected by polymerase chain reaction (PCR), the rare genetic variants were identified by sequencing. Results In our study, a total of 291 individuals were included. It could be shown that a significant increase in A2 M levels in the serum could be observed in the presence of a gene polymorphism (Pi*ZZ) and an alpha-1 antitrypsin serum level < 50 mg/dl compared to the healthy volunteers. Conclusions In this study, an inverse correlation between the serum levels of AAT and A2 M was found in the presence of a gene polymorphism (Pi*ZZ). Further studies are necessary to elucidate the clinical significance of increased A2 M serum levels in patients with severe AAT deficiency Pi*ZZ and rare gene variants whose AAT serum level is < 50 mg/dl.


Subject(s)
Pregnancy-Associated alpha 2-Macroglobulins/metabolism , alpha 1-Antitrypsin Deficiency/blood , Cohort Studies , DNA Mutational Analysis , Female , Genetic Variation/genetics , Homeostasis/physiology , Humans , Male , Middle Aged , Polymorphism, Genetic , Pulmonary Disease, Chronic Obstructive/blood , Pulmonary Disease, Chronic Obstructive/genetics , Reference Values , alpha 1-Antitrypsin/blood , alpha 1-Antitrypsin Deficiency/genetics
9.
Anaesth Intensive Care ; 45(1): 36-45, 2017 01.
Article in English | MEDLINE | ID: mdl-28072933

ABSTRACT

It has been recognised that vitamin D (VitD) has a potential role in the regulation of inflammation and protection from infection. In a prospective clinical observational pilot study, we investigated the serum levels of 25-hydroxyvitamin-D3 (25(OH)D3), 1,25-hydroxyvitamin-D3 (1,25(OH)2D3), parathyroid hormone (PTH), and cathelicidin in intensive care unit (ICU) patients with or without systemic inflammatory response syndrome (SIRS). We included 32 patients with SIRS (septic patients), 16 ICU patients without SIRS, and 16 healthy controls. To substantiate the findings of the clinical study, we stimulated monocyte-derived macrophages with microbial patterns and analysed the impact of VitD on release of cytokines and antimicrobial activity. We found that patients with or without SIRS had relatively low levels of 25(OH)D3 and 1,25(OH)2D3. Patients with sepsis had significantly lower levels of 25(OH)D3 as compared to ICU control patients and healthy controls (10.53 ± 11.3 µg/l versus 16.46 ± 12.58 µg/l versus 24.04 ± 12.07 µg/l); the same was true for 1,25(OH)2D3. Serum levels of PTH and cathelicidin were significantly increased in sepsis patients, as compared to the other groups. In vitro, VitD significantly decreased the release of pro-inflammatory cytokines from macrophages and increased the antimicrobial activity of the cells. We concluded that patients with sepsis have significantly lower VitD levels. In vitro, VitD modulates inflammation and increases the antibacterial activity of innate immune cells. These findings suggest that VitD insufficiency is mechanistically related to increased susceptibility to SIRS and sepsis.


Subject(s)
Parathyroid Hormone , Sepsis , Vitamin D , Humans , Pilot Projects , Prospective Studies , Systemic Inflammatory Response Syndrome
12.
Pneumologie ; 68(7): 492-5, 2014 Jul.
Article in German | MEDLINE | ID: mdl-25006842

ABSTRACT

Augmentation therapy in Alpha-1 Antitrypsin Deficiency aims to reduce the progression of lung emphysema, to reduce exacerbation frequency, and to improve quality of life. This expert statement briefly summarizes the most important treatment studies performed in patients with Alpha-1 Antitrypsin Deficiency and severe lung emphysema. Indications and contraindications for long-term intravenous augmentation therapy with human Alpha-1 Antitrypsin are derived from the available study results. Safety issues and the controversies of this topic are discussed in detail.


Subject(s)
Pulmonary Emphysema/etiology , alpha 1-Antitrypsin Deficiency/complications , alpha 1-Antitrypsin/administration & dosage , Enzyme Replacement Therapy , Evidence-Based Medicine , Humans , Infusions, Intra-Arterial , Pulmonary Emphysema/diagnosis , Serine Proteinase Inhibitors/administration & dosage , Serine Proteinase Inhibitors/adverse effects , Treatment Outcome , alpha 1-Antitrypsin/adverse effects , alpha 1-Antitrypsin Deficiency/diagnosis
14.
Internist (Berl) ; 55(4): 401-14, 2014 Apr.
Article in German | MEDLINE | ID: mdl-24577341

ABSTRACT

Chronic obstructive pulmonary disease (COPD) is a very common chronic disease with increasing prevalence. Inhaled particles and gases (in particular tobacco smoke) induce chronic inflammation of the airways accompanied by a not fully reversible airflow limitation. Destruction of lung tissue and deterioration of gas exchange may follow. In parallel, several comorbidities can be observed. The COPD assessment was revised and now takes into account lung function, the patients' symptoms, and history of exacerbations. More recently, several new long-acting bronchodilators received approval. Combination products, consisting of long-acting ß2-agonists and long-acting anticholinergics, and a new combination of a long-acting ß-agonist and an inhaled corticosteroid will follow in the near future. Smoking cessation is of central importance.


Subject(s)
Bronchodilator Agents/therapeutic use , Drug Approval , Drugs, Investigational/therapeutic use , Pulmonary Disease, Chronic Obstructive/drug therapy , Pulmonary Disease, Chronic Obstructive/physiopathology , Administration, Inhalation , Adrenal Cortex Hormones/therapeutic use , Adrenergic beta-Agonists/therapeutic use , Airway Resistance/drug effects , Cholinergic Antagonists/therapeutic use , Delayed-Action Preparations , Drug Combinations , Germany , Humans , Pulmonary Disease, Chronic Obstructive/diagnosis , Respiratory Function Tests , Smoking Cessation
15.
Dtsch Med Wochenschr ; 138(16): 837-41, 2013 Apr.
Article in German | MEDLINE | ID: mdl-23589046

ABSTRACT

A major problem associated with COPD is exacerbation. Symptoms include increased shortness of breathing, coughing, wheezing and sputum production. The frequency and severity of exacerbations are associated with a higher mortality risk. Early recognition and treatment have been shown to reduce severity of exacerbations, consecutive morbidity and hospital admissions. Telemonitoring of (nocturnal) lungsounds, oxygen saturation and frequency of breathing may offer the opportunity to detect symptoms of exacerbations very early. Therefore further research is needed to clarify precisely the role of telemonitoring in patients with COPD and exacerbations.


Subject(s)
Disease Progression , Polysomnography , Pulmonary Disease, Chronic Obstructive/diagnosis , Telemetry , Humans , Oxygen/blood , Prognosis , Pulmonary Disease, Chronic Obstructive/mortality , Pulmonary Disease, Chronic Obstructive/physiopathology , Respiratory Rate/physiology , Respiratory Sounds/physiopathology , Risk Factors
16.
Article in English | MEDLINE | ID: mdl-23055718

ABSTRACT

BACKGROUND: The major concept behind augmentation therapy with human α(1)-antitrypsin (AAT) is to raise the levels of AAT in patients with protease inhibitor phenotype ZZ (Glu342Lys)-inherited AAT deficiency and to protect lung tissues from proteolysis and progression of emphysema. OBJECTIVE: To evaluate the short-term effects of augmentation therapy (Prolastin) on plasma levels of AAT, C-reactive protein, and chemokines/cytokines. MATERIALS AND METHODS: Serum and exhaled breath condensate were collected from individuals with protease inhibitor phenotype ZZ AAT deficiency-related emphysema (n = 12) on the first, third, and seventh day after the infusion of intravenous Prolastin. Concentrations of total and polymeric AAT, interleukin-8 (IL-8), monocyte chemotactic protein-1, IL-6, tumor necrosis factor-α, vascular endothelial growth factor, and C-reactive protein were determined. Blood neutrophils and primary epithelial cells were also exposed to Prolastin (1 mg/mL). RESULTS: There were significant fluctuations in serum (but not in exhaled breath condensate) levels of AAT polymers, IL-8, monocyte chemotactic protein-1, IL-6, tumor necrosis factor-α, and vascular endothelial growth factor within a week of augmentation therapy. In general, augmented individuals had higher AAT and lower serum levels of IL-8 than nonaugmented subjects. Prolastin added for 3 hours to neutrophils from protease inhibitor phenotype ZZ individuals in vitro reduced IL-8 release but showed no effect on cytokine/chemokine release from human bronchial epithelial cells. CONCLUSION: Within a week, augmentation with Prolastin induced fluctuations in serum levels of AAT polymers and cytokine/chemokines but specifically lowered IL-8 levels. It remains to be determined whether these effects are related to the Prolastin preparation per se or to the therapeutic efficacy of augmentation with AAT.


Subject(s)
Enzyme Replacement Therapy , alpha 1-Antitrypsin Deficiency/drug therapy , alpha 1-Antitrypsin/administration & dosage , Adult , Aged , Biomarkers/blood , Breath Tests , C-Reactive Protein/metabolism , Cells, Cultured , Chemokines/blood , Cytokines/blood , Drug Administration Schedule , Female , Genotype , Germany , Humans , Infusions, Intravenous , Male , Middle Aged , Neutrophils/drug effects , Neutrophils/metabolism , Phenotype , Pulmonary Emphysema/blood , Pulmonary Emphysema/drug therapy , Pulmonary Emphysema/enzymology , Respiratory Mucosa/drug effects , Respiratory Mucosa/metabolism , Time Factors , Treatment Outcome , alpha 1-Antitrypsin/blood , alpha 1-Antitrypsin/genetics , alpha 1-Antitrypsin Deficiency/blood , alpha 1-Antitrypsin Deficiency/diagnosis , alpha 1-Antitrypsin Deficiency/enzymology , alpha 1-Antitrypsin Deficiency/genetics
17.
Internist (Berl) ; 53(11): 1364-70, 1373-5, 2012 Nov.
Article in German | MEDLINE | ID: mdl-22955248

ABSTRACT

Data about the clinical presentation of chronic obstructive pulmonary disease (COPD) have resulted in a new classification of the disease. The degree of airflow limitation has been amended by symptoms and exacerbation rate. The standard pharmacotherapy of stable COPD is in transition, as fixed combinations of long acting beta agonists and long acting anticholinergics are in the late stages of clinical development. On this background inhaled corticosteroids will need to be re-evaluated. Roflumilast is a recently approved therapeutic option that primarily diminishes exacerbation frequency in patients with chronic bronchitis and severe airflow obstruction (FEV(1) < 50%). In COPD patients with acute exacerbations procalcitonin levels can be used to guide antibiotic therapy. Comparable clinical outcomes can be achieved while using significantly less amounts of antibiotics.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Aminopyridines/therapeutic use , Benzamides/therapeutic use , Cholinergic Antagonists/therapeutic use , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/drug therapy , Cyclopropanes/therapeutic use , Humans
18.
Internist (Berl) ; 53(8): 924-33, 2012 Aug.
Article in German | MEDLINE | ID: mdl-22806148

ABSTRACT

Allergic diseases of the lungs may affect the airways, the pulmonary parenchyma and the pulmonary vessels. The most relevant representatives are allergic asthma, hypersensitivity pneumonitis, bronchopulmonary aspergillosis and the Churg-Strauss syndrome. The type of allergic reaction and the pathophysiological consequences vary considerably between these entities. New drugs target specific mechanisms based on new insights into the pathogenetic processes of the underlying disease.


Subject(s)
Asthma/diagnosis , Asthma/therapy , Hypersensitivity/diagnosis , Hypersensitivity/drug therapy , Pneumonia/diagnosis , Pneumonia/therapy , Humans
20.
Pneumologie ; 65(12): 751-5, 2011 Dec.
Article in German | MEDLINE | ID: mdl-22113451

ABSTRACT

BACKGROUND: Chronic diseases of the respiratory organs have, besides restrictions of lung function, also physical, mental and social consequences. The chronic disease impacts negatively not only the patient's own quality of life but also that of his/her partner and/or relative. As treatment modalities, besides drug therapy, above all outpatient rehabilitation measures have proved to be effective. In this pilot study we sought answers to three questions: (i) How is the quality of life of the patient's partner and/or relative influenced by the disease? How does the partner/relative assess the effect of the disease on the chronically ill patient? How does the partner/relative assess the effect of lung sports on the chronically ill patient? METHODS: A specially conceived questionnaire was given to the partners/relatives of 25 patients with chronic pulmonary diseases. The patients, 23 with chronic obstructive pulmonary disease and 2 with pulmonary fibrosis, have been participating in lung sports once a week for more than three years. The average age of the patients was 67 years. RESULTS: The patients' illness also negatively influenced the quality of life of the partner to a considerable extent. The impact of the patients' pulmonary disease on the healthy partner was assessed as being rather moderate. Restrictions of social life were essentially influenced by the amount of assistance required by the pulmonary patient. The therapeutic effects of lung sports on the well-being of the patient were aways considered to be positive by the respective partner/relatives. CONCLUSION: A chronic pulmonary illness also has a negative influence on the partner/relative's quality of life. The necessity for extensive assistance in daily life is accompanied by a considerable negative impact on the partner's quality of life. According to the opinion of the partner/relative, lung sports have positive effects in all of the chronically ill patient's fields of life.


Subject(s)
Activities of Daily Living/psychology , Attitude to Health , Lung Diseases/epidemiology , Lung Diseases/psychology , Quality of Life/psychology , Sports/psychology , Spouses/psychology , Spouses/statistics & numerical data , Aged , Chronic Disease , Female , Germany/epidemiology , Humans , Male , Prevalence , Sports/statistics & numerical data
SELECTION OF CITATIONS
SEARCH DETAIL
...